Trial
NCT01239108
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Phase IWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
Astex Pharmaceuticals, Inc.
Collaborators
—
Condition
Relapsed/Refractory Leukemias
Intervention
SGI-1776
Why stopped
The dose limiting toxicity of cardiac QTc prolongation was identified and demonstrated unsafe to continue clinical development of this molecule.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-02